Inherited forms of renal hypomagnesemia

Knoers, Nine V A M

Published in:
Pediatric Nephrology

DOI:
10.1007/s00467-008-0968-x

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2009

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):
Knoers, N. V. A. M. (2009). Inherited forms of renal hypomagnesemia: an update. Pediatric Nephrology, 24(4), 697-705. https://doi.org/10.1007/s00467-008-0968-x

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Inherited forms of renal hypomagnesemia: an update

Nine V. A. M. Knoers

Abstract The kidney plays an important role in ion homeostasis in the human body. Several hereditary disorders characterized by perturbations in renal magnesium reabsorption leading to hypomagnesemia have been described over the past 50 years, with the most important of these being Gitelman syndrome, familial hypomagnesemia with hypercalciuria and nephrocalcinosis, familial hypomagnesemia with secondary hypocalcemia, autosomal dominant hypomagnesemia with hypocalciuria, and autosomal recessive hypomagnesemia. Only recently, following positional cloning strategies in affected families, have mutations in renal ion channels and transporters been identified in these diseases. In this short review, I give an update on these hypomagnesemic disorders. Elucidation of the genetic etiology and, for most of these disorders, also the underlying pathophysiology of the disease, has greatly increased our understanding of the normal physiology of renal magnesium handling. This is yet another example of the importance of studying rare disorders in order to unravel physiological and pathophysiological processes in the human body.

Keywords Claudins · EGF · Gitelman syndrome · Hypomagnesemia · Mg²⁺ · Na/K-ATPase γ-subunit · NCC · TRPM6

Music and pathophysiology of magnesium handling

Magnesium (Mg²⁺) is the second-most abundant intracellular cation and plays an essential role in a wide variety of biological activities. Normal Mg²⁺ concentration (0.75–1.4 mmol/L) in the human body is balanced by changes in urinary Mg²⁺ excretion in response to altered uptake by the intestine. The main site of absorption is the small bowel where approximately one third of dietary Mg²⁺ is absorbed. Some additional absorption takes place in the large bowel. Absorption in the small bowel occurs via paracellular simple diffusion at high intraluminal concentrations and, at low concentrations, by active transcellular uptake via the recently identified Mg²⁺ channel TRPM6 (transient receptor potential channel melastatin 6), which is expressed along the brush border membrane of the small intestine [1]. Regulation and fine-tuning of serum the Mg²⁺ concentration occurs primarily in the kidney. Approximately 2500 mg of Mg²⁺ is filtered per day, of which 96% is reabsorbed along the nephron and only a small portion (5–15%) in the proximal tubule. The major site of passive reabsorption is the thick ascending limb (TAL) of Henle’s loop, where 50–72% of the filtered Mg²⁺ is reabsorbed through the paracellular pathway. Active reabsorption of Mg²⁺ takes place in the distal convoluted tubule (DCT) and accounts for 10% of the total filtered load. Because the DCT is the last site of Mg²⁺ reabsorption, the final urinary secretion of Mg²⁺ is determined here. The epithelial Mg²⁺ channel, TRPM6, is essential for the apical influx of Mg²⁺ in DCT cells. The mechanisms of cytosolic Mg²⁺ diffusion and basolateral transport of Mg²⁺ are not yet clear.

Hypomagnesemia is a common finding in hospitalized patients and often an acquired disorder resulting from deficient oral intake or accelerated urinary or intestinal loss. Acquired renal magnesium wasting is commonly caused by
drug therapy (i.e. diuretics, aminoglycosides, immunosuppressive agents), alcohol, and osmotic diuresis (i.e. diabetes mellitus). Hypomagnesemia has also recently been described as a frequent, and sometimes severe, side effect of cetuximab therapy, a monoclonal antibody against the epidermal growth factor receptor (EGFR) used in the treatment of colorectal cancer [2].

The most important genetic causes of hypomagnesemia are summarized in Table 1 and will be discussed in more detail below

**Hypomagnesemic disorders caused by defects localized in the TAL**

**Familial hypomagnesemia with hypercalciuria and nephrocalcinosis**

Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC; OMIM 248250) is an autosomal recessive renal disorder characterized by excessive renal Mg\(^{2+}\) wasting, resulting in persistent hypomagnesemia, renal Ca\(^{2+}\) wasting, bilateral nephrocalcinosis, and progressive renal failure [3–6]. Symptoms usually begin in the first few months of life. Affected individuals present with recurrent urinary tract infections, polyuria/polydipsia, nephrolithiasis, and/or failure to thrive. Additional symptoms at manifestation include abdominal pain, convulsions, muscular tetany, incomplete distal renal tubular acidosis, and hypocitraturia [3, 4, 7, 8]. Some authors have reported elevated serum parathyroid hormone levels early in the course of the disease [3, 7]. Hyperuricemia is observed in the majority of patients [3, 9, 10]. Ocular abnormalities (severe myopia, nystagmus and chorioretinitis) and hearing impairment have been reported as inconsistent extrarenal symptoms in FHHNC [6].

Renal function declines progressively in approximately 30% of FHHNC patients, and many of these patients reach end-stage renal disease in their teenage or young adult years [11]. Most patients with FHHNC are initially treated with oral citrate, thiazides, and high-dose enteral magnesium, which may normalize some biochemical abnormalities but do not always result in delayed progression of renal dysfunction [3, 6, 11, 12].

| Disease/OMIM\(^a\) | Gene/inheritance\(^b\) | Protein\(^b\) | Key clinical/biochemical symptoms |
|---------------------|------------------------|--------------|----------------------------------|
| Gitelman syndrome/ 263800 | SLC12A3/AR | NCC | Muscle weakness/tetany, Fatigue, Chondrocalcinosis, Hypomagnesemia, Hypocalciuria |
| Familial hypomagnesemia with hypercalciuria and nephrocalcinosis/ 248250/248190 | CLDN16/AR | Claudin-16 | Polyuria, Renal stones/nephrocalcinosis, Ocular abnormalities, Severe hypomagnesemia, Hypercalciuria |
| Autosomal dominant isolated renal Mg loss/ 154020 | FXYD2/AD | \(\gamma\)-Subunit sodium potassium ATPase | Seizures, Chondrocalcinosis, Hypomagnesemia, Hypocalciuria |
| Familial hypomagnesemia with secondary hypocalcemia/ 602014 | TRPM6/AR | Epithelial magnesium channel TRPM6 | Tetany/seizures, Hypomagnesemia, Hypocalciemia |
| Autosomal recessive isolated renal Mg loss | EGF/AR | Epidermal growth factor | Tetany/seizures, Hypomagnesemia, Normocalciuria |

\(^a\)Online Mendelian Inheritance in Man numbers. Available at: [http://www.ncbi.nlm.gov/omim/OMIM](http://www.ncbi.nlm.gov/omim/OMIM)

\(^b\)AR, Autosomal recessive; AD, autosomal dominant; SLC, solute carrier; EGF, epidermal growth factor; TRPM6, transient receptor potential channel melastatin 6, CLDN, claudin; NCC, NaCl cotransporter
Thus, the overall prognosis of FHHNC is poor, and a definite cure can only be achieved by renal transplantation.

In most cases, FHHNC is caused by loss-of-function mutations in the \textit{CLDN16} gene, which encodes claudin-16 (formerly paracellin-1), an important tight junction protein of the claudin family, that is expressed in the TAL of Henle’s loop and in the DCT \cite{11–14}. The claudin family comprises a set of structurally related proteins involved in the formation of tight junction proteins in various tissues \cite{15}. The mutations in \textit{CLDN16} identified in FHHNC patients consist of premature termination codons, splice-site mutations, and missense mutations, all of which are located within the extracellular loops or the transmembrane domains of the claudin-16 protein \cite{11–14}. In Germany and Eastern European countries a founder mutation (L151F) in the first extracellular loop of claudin-16 has been identified that is present in approximately 50% of mutant alleles \cite{11}. This finding greatly facilitates molecular diagnosis in patients originating from these countries. Konrad et al. recently reported that patients who have FHHNC and are affected by two loss-of-function mutations in the \textit{CLDN16} gene have an early onset of chronic renal failure, whereas patients with at least one mutation with residual function are protected from the rapid loss of renal function \cite{14}.

Interestingly, a novel homozygous \textit{CLDN16} mutation (T233R) has been identified in two families with self-limiting childhood hypercalciuria. The hypercalciuria decreased with age and was not associated with declined renal function. The T233R mutation is the first mutation to be identified in the cytosolic tail of claudin-16 and results in inactivation of the PDZ-domain-binding motif. This inactivation abolishes the association with the tight-junction scaffolding protein ZO-1, with subsequent accumulation of the mutant claudin-16 protein in lysosomes and no localization to the tight junction \cite{16}. These findings indicate that the clinical phenotype of mutations in claudin-16 is likely to be determined by the location of the mutation within the gene; mutations affecting amino acids at the extracellular and transmembrane segments cause classical FHHNC, while mutations affecting specific amino acids in the cytosolic domain cause a spontaneously resolving hypercalciuria.

In a subset of families with FHHNC and severe ocular involvement (OMIM 248190), the disease was shown to be caused by mutations in the \textit{CLDN19} gene, which encodes claudin-19, another important tight junction protein expressed in renal tubules and the eye \cite{17}.

The precise function of claudin-16 and -19 and their role in FHHNC remain to be elucidated. It was initially assumed that claudin-16 has high selective paracellular permeability for magnesium and calcium. However, based on the results of electrophysiological studies in LLC-PK1 epithelial cells expressing human claudin-16, Hou and coworkers reported that claudin-16 has only a low permeability for magnesium, but a much higher one for sodium. These researchers proposed that claudin-16 may form a paracellular shunt for sodium from the interstitium to lumen, thereby contributing to the lumen positive potential \cite{18}. This proposal was further substantiated in a mouse model with highly reduced claudin-16 expression, which displayed magnesiumuria and calcified, loss of bone mass, and nephrocalcinosis. Detailed analysis of the TAL function in this model revealed decreased paracellular sodium permeability and strongly reduced lumen positive potential \cite{19}. Taken together, these findings strongly suggest that claudin-16 is part of the tight junction complex that selectively mediates sodium backleak into the TAL lumen, thereby generating a higher lumen positive potential, which is critical for paracellular reabsorption of sodium and magnesium (Fig. 1).

### Hypomagnesemic disorders caused by defects localized in the DCT

**Gitelman syndrome**

Gitelman syndrome (GS) (OMIM 263800) is an autosomal recessive salt-losing renal tubulopathy that is characterized...
by hypomagnesemia, hypocalciuria, and secondary aldosteronism which is responsible for hypokalemia and metabolic alkalosis [20]. The prevalence is estimated at approximately 25 per million and, accordingly, the prevalence of heterozygotes is approximately 1% in Caucasian populations, making it one of the most frequent inherited renal tubular disorders [21].

Patients with GS usually present above the age of 6 years, and in many cases the diagnosis is only made at adult age. Most patients suffer from tetany, especially during periods of fever or when extra magnesium is lost due to vomiting or diarrhea. Paraesthesias, especially in the face, frequently occur. Some patients experience fatigue so severe that it interferes with daily activities, while others never complain of tiredness. The severity of fatigue in GS is not completely related to the degree of hypokalemia. In contrast to Bartter syndrome, which is a genetically distinct and clinically more severe tubular transport disorder that shares the hypokalemic metabolic alkalosis with GS, polyuria is usually absent or only mild in GS. In general, growth is normal in GS patients; however, it can be delayed in patients with severe hypokalemia and severe hypomagnesemia [22]. Many adult GS patients suffer from chondrocalcinosis, which is assumed to result from chronic hypomagnesemia [23]. This condition causes swelling, local heat, and tenderness over the affected joints. Cruz and colleagues have challenged the generally accepted idea that GS is a mild disorder [24]. They evaluated the symptoms and quality of life (QOL) in 50 adult patients with molecularly proven GS and compared this cohort of patients with 25 age- and sex-matched controls. They found that GS patients had significantly more complaints than controls, mainly salt craving, musculoskeletal symptoms, such as cramps, muscle weakness, and aches, and constitutional symptoms, such as fatigue, generalized weakness and dizziness, and nocturia and polydipsia. In addition, measures of QOL were significantly lower in GS patients than in controls.

Potassium and magnesium depletion prolong the duration of the action potential of cardiomyocytes and consequently increase the risk of developing ventricular arrhythmia. Electrocardiograms of patients with GS have shown that in about 50% of cases the QT interval is indeed slightly to moderately prolonged but, fortunately, is not associated with clinically relevant cardiac arrhythmias in the far majority of cases [25]. Sudden cardiac arrest has been reported in a few patients with GS [22, 26], indicating the advisability of systematic cardiac screening for such patients in order to identify other possible triggering mechanisms or underlying conditions. Blood pressure in GS patients is lower than in the general population, indicating that even the modest salt wasting of this disease reduces blood pressure. The results from a recent study in 35 GS carriers (with one mutant gene allele) suggest that GS carriers also have lower blood pressure and may be protected from hypertension [27]. Another study in a large cohort also demonstrated reduced blood pressure in subjects having one mutant gene allele [28]. These results are distinct from those reported in a previous study in an Amish kindred, in which no reduction of blood pressure was demonstrated in adult patients, despite increased Na⁺ excretion [29]. Thus, further studies are required to investigate whether the incidence of cardio-vascular events differs between GS patients or carriers compared to the control population.

The diagnosis of GS is based on clinical symptoms and biochemical abnormalities. The most typical biochemical abnormalities in GS patients are hypokalemia, hypomagnesemia, and hypocalciuria. Compared to Bartter syndrome, serum potassium concentration is comparably low (2.7 ± 0.4 mmol/L). Serum magnesium concentration is low (less than 0.65 mmol/L). In a small number of GS patients it is possible to easily maintain the magnesium concentration in the normal range early on, which may lead to a false diagnosis of Bartter syndrome; in these patients, the magnesium concentration only drops below normal with time (personal observation). Hypomagnesemia and hypocalciuria have always been considered obligate features for GS. This assumption has been disputed by Lin et al. [30] who reported two families with molecularly proven GS in which male patients had severe hypokalemia and were symptomatic with episodes of paralysis, impaired urinary concentration ability, but with normal serum magnesium and urinary calcium excretion. Remarkably, female GS patients within these families, carrying the same causative mutations as the male patients, were asymptomatic, had less severe hypokalemia, and maintained intact urine concentration ability, but they did have hypomagnesemia and hypocalciuria [30]. Although this was a small study, the authors concluded that gender may affect phenotypic expression in GS and that hypomagnesemia and hypocalciuria may not be invariant features of the disorder.

Prostaglandin excretion is normal, and plasma renin activity and plasma aldosterone concentration are only slightly elevated compared to Bartter syndrome. Renal functional studies have demonstrated a normal or slightly decreased urinary concentrating mechanism, but clearly reduced distal fractional chloride reabsorption during hypotonic saline infusion. Patients with GS have a blunted natriuretic response to hydrochlorothiazide administration, but a prompt natriuresis after administration of furosemide, indicating that the defect in GS is located at the level of the distal tubule.

Most patients with GS remain untreated. However, in view of the assumption that chondrocalcinosis is due to magnesium deficiency, there is a clear argument for lifelong
supplementation of magnesium. Normalization of serum magnesium is difficult to achieve since high doses of magnesium cause diarrhea. The bioavailability of magnesium preparations is different. Magnesium oxide and magnesium sulfate have a significantly lower bioavailability than magnesium chloride, magnesium lactate, and magnesium aspartate [31]. Hypokalemia can be treated by drugs that antagonize the activity of aldosterone or block the epithelial sodium channel (ENaC) in the collecting duct. We prefer the combination of amiloride with KCl.

In general, the long-term prognosis of GS is good. However, the severity of fatigue may seriously hamper some patients in their daily activities. Progression to renal insufficiency is extremely rare in GS. As yet, only one patient who developed chronic renal insufficiency and subsequent progression to end-stage renal disease has been reported [32].

In the great majority of cases, GS is caused by mutations in the solute carrier family 12, member 3, SLC12A3 gene, which encodes the renal thiazide-sensitive sodium chloride cotransporter (NCC) that is specifically expressed in the apical membrane of cells in the first part of the DCT (reviewed in [33]). The NCC is a 1021-amino acid polypeptide, and the two-dimensional structure is predicted to contain 12 transmembrane domains and long intracellular amino- and carboxy-termini [34]. At present, more than 140 different putative loss-of-function mutations in the SLC12A3 gene have been identified in GS patients (collected in Human Gene Mutation Database HGMD, http://www.hgmd.cf.ac.uk/). Most are missense mutations substituting conserved amino acid residues within putative functional domains of NCC, whereas nonsense, frameshift-, and splice-site mutations and gene rearrangements are less frequent.

Functional expression studies and immunocytochemistry analyses of Xenopus leavis oocytes revealed that most disease-causing NCC mutants belong to the so-called type 2 mutations. These type 2 mutations are missense mutations or insertions/deletions of one or more nucleotide triplets, resulting in fully translated proteins. Due to the mutation, however, these mutant receptors are misfolded and retained in the endoplasmic reticulum (ER), as the ER is the organelle that has the cellular quality control over proper folding and maturation of synthesized proteins. Misfolded proteins are subsequently targeted for proteasomal degradation. De Jong and coworkers have shown that NCC misfolding resulting in defective trafficking to the plasma membrane in GS is not uniformly complete [35]. Some mutant NCC proteins are only partially retarded in their trafficking; they do reach the plasma membrane, albeit to a limited extent, and are partially active. It was subsequently demonstrated that the intrinsic activity of these partially retarded mutants is unaffected by the mutation [36, 37]. This finding opens the possibility of using pharmaceutical chaperones that facilitate the routing of trafficking-defective—but otherwise functional—NCC proteins to the apical membrane for therapeutic use.

Another class of mutations in GS has been recently identified by Riveira-Munoz et al. [38]. This newly identified class includes mutants that are partly retained in the cell. In contrast to the mutants mentioned above, however, these mutants do not show any functional activity and, consequently, pharmacological chaperones will not be of any therapeutic use.

In general, there is extreme inter- and intrafamilial phenotype variability in GS, the latter emphasizing the lack of a correlation between the severity of symptoms in GS and the type of mutation in the SLC12A3 gene [30]. Recently, however, Riveira-Munoz et al. described a small subgroup of patients with a remarkable severe phenotype, including an early onset, severe neuromuscular manifestations, growth retardation, and ventricular arrhythmias [22]. The majority of these patients was male and carried at least one splice-site mutation, resulting in a truncating transcript, or a non-functional intracellularly retained mutation. Based on their data, these researchers suggested that the nature/position of the SLC12A3 mutation combined with male gender may be a determinant factor in the severity of GS. Studies in larger cohorts are necessary to confirm this proposal.

A minority of patients with the Gitelman phenotype has been shown to have mutations in the CLCNKB gene, which encodes the renal chloride channel CIC-Kb, located in basolateral membrane of cells of the TAL of Henle’s loop and the distal tubules. Mutations in the CLCNKB gene were originally found to be the cause of classic Bartter syndrome [39, 40]. It is now evident that the clinical phenotype in patients with CLCNKB mutations can be highly variable, varying from an antenatal onset of Bartter syndrome on one side of the spectrum to a phenotype closely resembling GS on the other side (review in [33]). Therefore, there is a medical indication to screen the CLCNKB gene in patients with the Gitelman phenotype who do not have mutations in the SLC12A3 gene.

Both loss-of-function mutations in NCC and mutations in CLC-Kb lead to disruption of NaCl reabsorption in the DCT (Fig. 2). When less NaCl is reabsorbed, more sodium will arrive in the collecting duct, resulting in mild volume contraction. The reduced vascular volume activates the renin–angiotensin system, increasing renin activity and aldosterone levels. The elevated aldosterone levels give rise to increased electrogenic sodium reabsorption in the cortical collecting duct via the ENaC, defending salt homeostasis at the expense of increased secretion of potassium and hydrogen ions, thus resulting in hypokalemia and metabolic alkalosis.

Passive Ca\(^{2+}\) reabsorption in the proximal tubule and reduced abundance of the epithelial Mg\(^{2+}\) channel TRPM6,
Autosomal dominant renal hypomagnesemia with hypocalciuria

Autosomal dominant renal magnesium wasting (HOMG2; OMIM 154020), is characterized by hypomagnesemia due to renal magnesium loss and is associated with hypocalciuria [42]. Patients may suffer from generalized convulsions, but they may also be asymptomatic, except for the symptoms and normalization of calcium metabolism [52]. Untreated, the disease may be fatal or may lead to severe neurological damage [51, 52]. The disease typically manifests during the first months of life with generalized convulsions or signs of increased neuromuscular excitability, such as muscle spasms or tetany [51]. Untreated, the disease may be fatal or may lead to severe neurological damage [51, 52].

The exact molecular mechanism of hypomagnesemia and the associated hypocalciuria in patients with FXYD2 mutations remains to be elucidated. It has been speculated that abrogation of γ-mediated modulation of the Na-K-ATPase kinetics changes the electrochemical gradients of Na+ and K+, with a secondary reduction in Mg2+ reabsorption through the apical TRPM6 channel [47].

Kantorovich et al. recently described another family with autosomal dominant isolated hypomagnesemia, in which they excluded linkage to the chromosomal region of 11q23 containing the FXYD2 gene [48]. Thus, there is clear evidence for locus heterogeneity for this phenotype.

Familial hypomagnesemia with secondary hypocalcemia

Familial hypomagnesemia with secondary hypocalcemia (HSH) is a rare autosomal recessive disorder that manifests in the newborn period and is characterized by very low serum Mg2+ (0.2 mmol/L) [49]. Hypocalcemia is another characteristic feature of this disorder and is a secondary consequence of parathyroid failure and parathyroid hormone (PTH) resistance as a result of chronic, severe hypomagnesemia [50]. The disease typically manifests during the first months of life with generalized convulsions or signs of increased neuromuscular excitability, such as muscle spasms or tetany [51]. Untreated, the disease may be fatal or may lead to severe neurological damage [51, 52].

The immediate administration of magnesium, usually via the intravenous route, followed by lifelong-treatment with high-dose oral magnesium assures the relief of clinical symptoms and normalization of calcium metabolism [52]. In contrast, serum magnesium levels usually fail to reach normal values under oral substitution therapies and remain in the subnormal range (0.5–0.6 mmol/L).
Familial HSH is caused by mutations in the TRPM6 gene, which encodes the TRPM6 protein [51, 53, 54]. This protein belongs to the melastatin-related group of a large family of transient receptor potential (TRP) cation channels that play an important role in a wide variety of physiological processes, ranging from thermal, tactile, taste, osmolar, and fluid flow sensing to transepithelial Ca\(^{2+}\) and Mg\(^{2+}\) transport [55]. Detailed electrophysiological analyses and expression studies have demonstrated that TRPM6 confines a Mg\(^{2+}\)-permeable channel, which is specifically localized to the apical membrane of Mg\(^{2+}\)-reabsorbing tubules in the kidney (DCT) and the brush-border membrane of the Mg\(^{2+}\)-absorptive cells in the small intestine [1] (Fig. 2). By far the majority of mutations found in HSH patients introduce stop codons, deletions of exons, and frameshifts or affect splice sites, thus resulting in a complete loss-of-function of TRPM6 protein [51]. These inactivation mutations cause the combination of impaired gut reabsorption of Mg\(^{2+}\) and renal wasting seen in HSH.

**Isolated autosomal recessive hypomagnesemia (IRH)**

The disease gene in a very rare form of primary hypomagnesemia, called isolated autosomal recessive renal hypomagnesemia (IRH; OMIM 611718), has very recently been identified. This disease was identified 20 years ago in two Dutch sisters from consanguineous parents, who showed psychomotor retardation and epileptic seizures during childhood and who as adults were moderately mentally retarded [56]. Both affected sisters had very low serum Mg\(^{2+}\) levels, while their urinary Mg\(^{2+}\) excretion was in the normal range, pointing to a disturbance in the tubular reabsorption of Mg\(^{2+}\). Apart from hypomagnesemia, no other abnormalities were identified and, in particular, there was no disturbance in urinary calcium excretion. Using a whole genome homozygosity-based mapping strategy followed by fine-mapping, Groenestege et al. identified a critical linkage region of 25.7 cM on chromosome 4. Within this region, the EGF gene encoding the pro-epidermal growth factor (pro-EGF) was proven to be the disease gene, based on the identification of a homozygous mutation, C3209T in exon 22 in both affected sisters. This mutation caused the substitution of the highly conserved proline 1070 within the cytoplasmic tail of pro-EGF by leucine (P1070L). Both of parents of the patient, as well as the unaffected sisters were heterozygous for the mutation [57].

Pro-epidermal growth factor is a type-one membrane protein that is expressed at high level in the luminal and at a low level at the basolateral membranes of the DCT [58–60]. It is cleaved by extracellular proteases to generate the active EGF in luminal and basolateral spaces. In a kidney cell line, Groenstege et al. demonstrated that EGF binding to its receptor (EGFR) is essential for the function of TRPM6, which controls magnesium reabsorption in the kidney [57]. As a result of the IRH-associated P1070L mutation, pro-EGF targeting to the basolateral membrane is disrupted, thereby leading to reduced EGF production in the basolateral space and, consequently, inadequate stimulation of the EGFR on the basolateral membrane. As a result, TRPM6 is insufficiently activated, causing magnesium loss. This model is compatible with the hypomagnesemia previously observed in colon cancer patients treated with the anti-EGF receptor antibody cetuximab [2]. In support of this mechanism, it has been shown that cetuximab also antagonizes the stimulation of TRPM6 activity by EGF in cultured cells [57].

**Conclusion**

The etiology and pathophysiology of a significant number of inherited disorders associated with disturbances of renal magnesium transport has been elucidated in recent years. With the knowledge that has been gained, our insight into the physiology of renal magnesium handling has increased significantly. Nevertheless, the molecular mechanisms responsible for the basolateral extrusion of magnesium in the distal convoluted tubule are still completely unknown. Future identification of gene defects in other forms of renal magnesium loss, proven not to be caused by the known disease genes, will be of great help in finding these pieces in the magnesium-transport puzzle.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

**References**

1. Voets T, Nilius B, Hoefs S, van der Kemp AW, Droogmans G, Bindels RJ, Hoenderop JG (2004) TRPM6 forms the Mg\(^{2+}\) influx channel involved in intestinal and renal Mg\(^{2+}\) absorption. J Biol Chem 279:19–25
2. Tejpar S, Piessevaux H, Claes K, Pironot P, Hoenderop JG, Verslype C, Van Cutsem E (2007) Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 8:387–394
3. Praga M, Vara J, González-Parra E, Andrés A, Alamo C, Araque A, Ortiz A, Rodicio JL (1995) Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Kidney Int 47:1419–1425
4. Manz F, Scharer K, Janka P, Lombeck J (1978) Renal magnesium wasting, incomplete tubular acidosis, hypercalciuria, and nephrocalcinosis in siblings. Eur J Pediatr 128:67–79
5. Evans RA, Carter JN, George CR, Walls RS, Newland RC, McDonnell GD, Lawrence JR (1981) The congenital “magnesium-losing kidney”. Report of two patients. QJM 50:39–52
6. Benigno V, Canonica CS, Bettinelli A, von Vigier RO (2000) Hypomagnesemia-hypercalciuria-nephrocalcinosis: a report of nine cases and a review. Nephrol Dial Transplant 15:605–610
7. Michels MF, Drash AL, Linarelli LG, De Rubertis FR, Davis BB (1972) Decreased bicarbonate threshold and renal magnesium wasting in a sibling with distal renal tubular acidosis: evaluation of the pathophysiological role of parathyroid hormone. Metabolism 21:905–920
8. Rodriguez-Soriano J, Vallo A (1994) Pathophysiology of the renal acidification defect present in the syndrome of familial hypomagnesemia-hypercalciuria. Pediatr Nephrol 8:431–435
9. Ullmann A, Hadji S, Lacour B, Bourdeau A, Bader C (1985) Renal magnesium and phosphate wastage in a patient with hypercalciuria and nephrocalcinosis: effect of oral phosphorus and magnesium supplements. Nephron 40:83–87
10. Rodriguez-Soriano J, Vallo A, Garca-Fuentes M (1987) Hypomagnesemia of hereditary renal origin. Pediatr Nephrol 1:465–471
11. Weber S, Schneider L, Peters M, Misselwitz J, Rönnedarth G, Böswald M, Bonzel KE, Seeman T, Sulakova T, Kuvertz-Bröking E, Gregoric A, Palcoux JB, Tasic V, Manz F, Schärer K, Seyberth HW, Konrad M (2001) Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol 12:1872–1881
12. Kang JH, Choi HJ, Cho HY, Lee JH, Sa IS, Cheig HI, Choi Y (2005) Familial hypomagnesemia with hypercalciuria and nephrocalcinosis associated with CLDN16 mutations. Pediatr Nephrol 20:1490–1493
13. Simon DB, Lu Y, Choute KA, Velazquez H, Al-Sabban E, Praga M, Casari G, Bettinelli A, Colussi G, Rodriguez-Soriano J, McRedie D, Milford D, Sanjad S, Lifton RP (1999) Paracellin-1 a renal tight junction protein required for paracellular Mg2+ resorption. Science 285:103–106
14. Konrad M, Hou J, Weber S, Dötsch J, Kari JA, Seeman T, Kuvertz-Bröking E, Pecco-Antic A, Tasic V, Dittrich K, Alshaya HO, von Vigier RO, Gallati S, Goodenough DA, Schaller A (2008) CLDN16 genotype predicts renal decline in familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol 19:171–181
15. Morita KA, Furuse M, Fukimoto K, Tsukita S (1999) Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci USA 96:511–516
16. Muller D, Kausalya J, Claverie-Martin F, Meij IC, Eggert P, Garcia-Nieto V, Hunziker W (2003) A novel claudin 16 mutation associated with childhood hypercalciuria abolished binding to ZO-1 and results in lysosomal mistargeting. Am J Hum Genet 73:1293–1301
17. Konrad M, Schaller A, Seelow D, Pandev AV, Waldegger S, Lesslauer A, Vitzthum H, Suzuki Y, Luk JM, Becker C, Schlingmann KP, Schmid M, Rodriguez-Soriano J, Ariceta G, Cano F, Enriquez R, Juppmann H, Bakkaloglu SA, Hediger MA, Gallati S, Neuhaus SC, Nurnberg P, Weber S (2006) Mutations in the tight junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am J Hum Genet 79:949–957
18. Hou J, Paul DL, Goodenough DA (2005) Paracellin-1 and the modulation of ion selectivity of tight junctions. J Cell Sci 118:5109–5118
19. Hou J, Shan Q, Wang T, Gomes AS, Yan Q, Paul DL, Bleigh M, Goodenough DA (2007) Transgenic RNAi depletion of claudin-16 and the renal handling of magnesium. J Biol Chem 282:17114–17122
20. Gitelman HJ, Graham JB, Welt LG (1966) A familial disorder characterized by hypokalemia and hypomagnesemia. Trans Assoc Am Physicians 79:221–235
21. Melander O, Ohro-Melander M, Bengtsson K, Lindblad U, Rastam L, Groop L, Hulten UL (2000) Genetic variants of thiazide-sensitive NaCl cotransporter in Gitelman’s syndrome and primary hypertension. Hypertension 36:389–394
22. Riveira-Munoz E, Chang Q, Godefroid N, Hoenderop JG, Bindels RJ, Dahan K, Devuyst O (2007) Belgian Network for Study of Gitelman Syndrome. Transcriptional and functional analyses of SLC12A3 mutations: new clues for the pathogenesis of Gitelman syndrome. J Am Soc Nephrol 1:1271–1283
23. Calò L, Punzi L, Semplicini A (2000) Hypomagnesemia and chondrocalcinosis in Bartter’s and Gitelman’s syndrome: review of the pathogenetic mechanisms. Am J Nephrol 20:347–350
24. Cruz-DN, Shaer AJ, Bia MJ, Lifton RP, Simon DB (2001) Gitelman’s syndrome revisited: an evaluation of symptoms and health-related quality of life. Kidney Int 59:710–717
25. Foglia PEG, Bettinelli A, Tosetto C, Cortesi C, Cossazso L, Edefonti A, Bianchetti MG (2004) Cardiac work up in primary hypokalemia-hypomagnesemia (Gitelman syndrome). Nephrol Dial Transplant 19:1398–1402
26. Scognamiglio R, Negut C, Calò L (2007) Aborted sudden cardiac death in two patients with Bartter’s/Gitelman’s syndromes. Clin Nephrol 67:193–197
27. Fava C, Montagnana M, Rosberg L, Burri P, Almgren P, Jönsson A, Vanbey B, Lippi G, Minuz P, Hulten L, Auréll M, Melander O (2008) Subjects heterozygous for genetic loss of function of the thiazide-sensitive cotransporter have reduced blood pressure. Hum Mol Genet 17:413–418
28. Ji W, Foo JN, O’Reak BJ, Zhao H, Larson MG, Simon DB, Newton-Cheh C, State MW, Levy D, Lifton RP (2008) Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet 40:592–599
29. Cruz-DN, Simon DB, Nelson-Williams C, Farhi A, Finberg K, Burleson L, Gill JR, Lifton RP (2001) Mutations in the Na+-Cl− cotransporter reduce blood pressure in humans. Hypertension 37:1458–1464
30. Lin SH, Cheng NL, Hsu YJ, Halperin ML (2004) Intracellular phenotype variability in patients with Gitelman syndrome having the same mutations in their thiazide-sensitive sodium/chloride cotransporter. Am J Kidney Dis 43:304–312
31. Firoz M, Braber M (2001) Bioavailability of U.S. commercial magnesium preparations. Magnesium Res 4:257–262
32. Bonfante L, Davis PA, Spinello M, Antonello A, D’Angelo A, Semplicini A, Galo L (2001) Chronic renal failure, end-stage renal disease, and peritoneal dialysis in Gitelman’s syndrome. Am J Kidney Dis 38:165–168
33. Knoers NVAM, Starremans PGJF, Mommsen LAH (2005) Hypokalemic tubular disorders. In Davidson AM, Cameron JS, Grunfeld J-P, Ponticelli C, Ritz E, Winears CG, van Ypersele C (eds) Oxford textbook in clinical nephrology, 3rd edn. Oxford University Press, Oxford, pp 995–1004
34. Gamba G, Saltzberg SN, Lombardi M, Miyanoshita A, Lytton J, Hediger MA, Brenner BM, Hebert SC (1993) Primary structure and functional expression of a cDNA encoding the thiazide-sensitive, electroneutral sodium-chloride cotransporter. Proc Natl Acad Sci USA 90:2749–2753
35. de Jong JC, van der Vliet WA, van den Heuvel LPWJ, Willems PHGM, Knoers NVAM, Bindels RJM (2002) Functional expression of mutations in the human NaCl cotransporter (NCC): evidence for impaired routing mechanisms in Gitelman’s syndrome. J Am Soc Nephrol 13:1442–1448
36. de Jong JC, Willems PHGM, Mooren FJM, van den Heuvel PWJ, Knoers NVAM, Bindels RJM (2003) The structural unit of the thiazide-sensitive NaCl cotransporter (NCC) is a homodimer. J Biol Chem 278:24302–24307
